![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
EB-003 is a novel 5-HT2A receptor agonist which is currently being evaluated in preclinical studies for the treatment of depression and anxiety disorders.
Lead Product(s): EB-003
Therapeutic Area: Psychiatry/Psychology Product Name: EB-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Details:
MindBio will seek to advance a drug candidate EB-002 (Psilocin Prodrug). Currently, it is being evaluated in the early-stage clinical trials studies for the treatment of depression, anxiety.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-002
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: MindBio Therapeutics
Deal Size: $66.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 14, 2024
Details:
Enveric plans to continue to focus and invest in the development of its lead candidates EB-003, a first-in-class neuroplastogen designed to eliminate hallucinations, and EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin.
Lead Product(s): EB-003
Therapeutic Area: Psychiatry/Psychology Product Name: EB-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Divestment January 23, 2024
Details:
EB-003 is a novel 5-HT2A receptor agonist which is currently being evaluated in preclinical studies for the treatment of depression and anxiety disorders.
Lead Product(s): EB-003
Therapeutic Area: Psychiatry/Psychology Product Name: EB-003
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 03, 2024
Details:
EB-373 (psilocybin prodrug) is an oral 5-HT2A receptor agonist. It is being evaluated in preclinical studies for the treatment of generalized anxiety disorder.
Lead Product(s): Psilocybin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 27, 2023
Details:
Enveric lead product candidate EVM301, which is a 5-HT2A receptor modulator small molecule drug candidate. It is being evaluated for the treatment of anxiety.
Lead Product(s): EVM301
Therapeutic Area: Psychiatry/Psychology Product Name: EVM301
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Details:
EB-373, is a new chemical entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target psychiatric disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 18, 2023
Details:
EB-373, is a new chemical entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 21, 2023
Details:
EB-373, is a New Chemical Entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed leveraging the company’s Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2023
Details:
EB-373 is a New Chemical Entity (NCE), designed as a next-generation proprietary psilocin prodrug and developed by leveraging its Psybrary™ drug discovery platform to target anxiety disorders.
Lead Product(s): Psilocybin Prodrug
Therapeutic Area: Psychiatry/Psychology Product Name: EB-373
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 17, 2023